Affiliation: Mayo Clinic
- Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 TrialNandita Khera
Department of Hematology Oncology, Mayo Clinic, Phoenix, Arizona Electronic address
Biol Blood Marrow Transplant 21:1815-22. 2015..Despite differences in certain baseline characteristics, survival was comparable between study participants and nonparticipants. The results of the BMT CTN trial appear generalizable to the population of trial-eligible patients...
- From evidence to clinical practice in blood and marrow transplantationNandita Khera
College of Medicine, Mayo Clinic, 5777 E Mayo Blvd, Phoenix, AZ 85054, USA Electronic address
Blood Rev 29:351-7. 2015....
- Financial burden in recipients of allogeneic hematopoietic cell transplantationNandita Khera
Division of Hematology Oncology, Mayo Clinic, Phoenix, Arizona Electronic address
Biol Blood Marrow Transplant 20:1375-81. 2014..Future research should investigate potential interventions to help at-risk patients and prevent adverse financial outcomes after this life-saving procedure. ..
- Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimensNandita Khera
Division of Hematology Oncology, Mayo Clinic in Arizona, Phoenix, Arizona, USA Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts, USA Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Oncologist 19:639-44. 2014..Use of unrelated/alternative donors, transplant for diseases other than lymphoma or myeloma, and acute GVHD were predictors for higher early costs, and extensive chronic GVHD and death were associated with higher late costs. ..
- Costs of second allogeneic hematopoietic cell transplantationNandita Khera
Division of Hematology Oncology, Mayo Clinic in Arizona, Phoenix, AZ, USA
Transplantation 96:108-15. 2013....
- Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantationNandita Khera
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
J Clin Oncol 30:71-7. 2012..Our objective was to describe the incidence of nonmalignant late complications and their association with health and functional status in a recent cohort of hematopoietic cell transplantation (HCT) survivors...
- Economics of hematopoietic cell transplantationNandita Khera
Division of Hematology Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA
Blood 120:1545-51. 2012..We discuss the need for more value-based assessments of HCT using high-quality approaches to measuring costs and outcomes so that potential future efforts to contain costs are well informed and appropriate...
- Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantationEric J Chow
Eric J Chow, K Scott Baker, Stephanie J Lee, Mary E D Flowers, Kara L Cushing Haugen, Yoshihiro Inamoto, Wendy M Leisenring, Karen L Syrjala, and Paul J Martin, Fred Hutchinson Cancer Research Center Eric J Chow, K Scott Baker, Seattle Children s Hospital Eric J Chow, K Scott Baker, Stephanie J Lee, Mary E D Flowers, and Paul J Martin, University of Washington, Seattle, WA and Nandita Khera, Mayo Clinic, Phoenix, AZ
J Clin Oncol 32:191-8. 2014..To determine the influence of modifiable lifestyle factors on the risk of cardiovascular disease after hematopoietic cell transplantation (HCT)...
- Impact of race and ethnicity on outcomes and health care utilization after allogeneic hematopoietic cell transplantationNandita Khera
Mayo Clinic in Arizona, Phoenix, AZ, USA
Leuk Lymphoma 56:987-92. 2015..Health care utilization was comparable between the two groups. Homogeneity of medical care for allogeneic HCT may help overcome racial/ethnic disparities, but not those due to patients' primary insurance. ..
- Clinical benefit of response in chronic graft-versus-host diseaseYoshihiro Inamoto
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Electronic address
Biol Blood Marrow Transplant 18:1517-24. 2012..Modification of the algorithm or validation of other more meaningful clinical endpoints is warranted for future clinical trials of treatment for chronic graft-versus-host disease...
- Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host diseaseAreej El-Jawahri
Division of Bone Marrow Transplantation, Massachusetts General Hospital Cancer Center, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts Electronic address
Biol Blood Marrow Transplant 20:1341-8. 2014..Therefore, we did not find evidence that older age is associated with worse outcomes in patients with moderate or severe chronic GVHD. ..
- Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antJames L Slack
Division of Hematology and Oncology, Mayo Clinic Arizona, Phoenix, AZ 85054, USA
Biol Blood Marrow Transplant 19:1167-74. 2013..We conclude that FBM-A is an effective and safe conditioning regimen for adults up to age 69 with hematologic malignancies who have low-, intermediate-, or high-risk scores according to the DRI. ..
- Validation of measurement scales in ocular graft-versus-host diseaseYoshihiro Inamoto
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Ophthalmology 119:487-93. 2012..Candidate scales were recommended for use in clinical trials by the National Institutes of Health (NIH) Chronic GVHD Consensus Conference or have been previously validated in dry eye syndromes...
- Factors associated with adherence to preventive care practices among hematopoietic cell transplantation survivorsNandita Khera
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
Biol Blood Marrow Transplant 17:995-1003. 2011..Future efforts to improve adherence should address concerns about medical costs and lack of knowledge, two major modifiable predictors of lower adherence to preventive care practices in HCT survivors...
- Hospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: comparison among alternative graft sourcesKaren K Ballen
Department of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts
Biol Blood Marrow Transplant 20:1819-27. 2014..These data provide insight into the resource needs of patients who undergo HCT with these various graft sources...
- Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromesChristine N Duncan
Department of Pediatric Stem Cell Transplant, Dana Farber Cancer Institute, Boston, Massachusetts
Biol Blood Marrow Transplant 21:151-8. 2015..However, they continue to be at risk for relapse and nonrelapse morbidity and mortality. Novel approaches are needed to minimize relapse risk and long-term transplantation morbidity in this population. ..
- Limiting the daily total nucleated cell dose of cryopreserved peripheral blood stem cell products for autologous transplantation improves infusion-related safety with no adverse impact on hematopoietic engraftmentNandita Khera
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, Seattle, WA 98109, USA
Biol Blood Marrow Transplant 18:220-8. 2012..We conclude that limiting the daily TNC dose improved the safety of this procedure without compromising engraftment or increasing the costs of the procedure...